Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION® Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].

According to IQVIA® sales data for the 12-month period ending May 2026, the BRIDION® Injection, 100 mg/mL market achieved annual sales of approximately $1.6 billion*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "The launch of Sugammadex Injection represents a significant addition to Glenmark's growing U.S. injectables portfolio and strengthens our presence in the hospital and institutional segment. Achieving a Day 1 launch reflects the agility, preparedness and execution discipline behind our injectable strategy. It also underscores our ability to identify meaningful market opportunities, support greater supply reliability and expand access to high-quality and affordable medicines across the U.S healthcare system."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 2191.05 as compared to the previous close of Rs. 2261.95. The total number of shares traded during the day was 15794 in over 2093 trades.

The stock hit an intraday high of Rs. 2268.80 and intraday low of 2185.00. The net turnover during the day was Rs. 35071204.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035